Monoclonal antibodies against COVID-19
Previous experience on SARS and MERS coronaviruses is proving instrumental for the rapid development of new diagnostic, prophylactic and therapeutic intervention strategies against COVID-19. The EU-funded MANCO project is building on technology generated during the ongoing IMI-funded ZAPI project on monoclonal antibodies against coronaviruses. The researchers of MANCO will identify specific monoclonal antibodies against the new coronavirus and validate them at the preclinical level. The idea is to advance one lead prophylactic and/or therapeutic monoclonal antibody into a Phase I clinical trial and make results available within two years of the start of the project.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
3605 LT Maarssen